The optimal sequencing of bispecific antibodies and CAR T-cell therapy is a critical area of investigation in the treatment of relapsed/refractory multiple myeloma. Recent data from cohort C of the CARTITUDE-2 study, along with real-world evidence, are helping to inform treatment strategies. These studies aim to maximize patient outcomes by strategically using these advanced therapies.
CARTITUDE-2 Cohort C Insights
Shaji Kumar, MD, reviewed data from cohort C of the CARTITUDE-2 study, which evaluated ide-cel in patients with relapsed/refractory multiple myeloma. The results showed promising efficacy, providing valuable insights into the potential role of ide-cel in the treatment sequence. Understanding the outcomes in this cohort is essential for determining how to best position CAR T-cell therapy relative to other treatment options, such as bispecific antibodies.
Real-World Evidence
In addition to clinical trial data, real-world studies are playing a crucial role in evaluating the effectiveness and safety of ide-cel. These studies capture the experiences of a broader range of patients, including those who may not have been eligible for clinical trials. By analyzing real-world data, clinicians can gain a more comprehensive understanding of how ide-cel performs in diverse patient populations and identify potential predictors of response or resistance.
Sequencing Strategies and Future Trials
Determining the optimal sequence of bispecific antibodies and CAR T-cell therapy is a complex challenge. Factors such as patient characteristics, disease burden, and prior treatment history must be considered. Future clinical trials should focus on identifying predictive biomarkers that can help guide treatment decisions and personalize therapy. These trials should also explore novel combinations and sequencing strategies to further improve outcomes for patients with multiple myeloma.
